Intestinal diseases—from inflammatory bowel disease to parasitic infections and food intolerances—cause significant welfare compromise through chronic gastrointestinal signs. Systematic diagnosis enables targeted management rather than symptomatic treatment.
Small intestinal inflammatory bowel disease causes weight loss, vomiting, and diarrhoea from malabsorption and mucosal inflammation. Protein-losing enteropathy (PLE) is a severe welfare emergency where albumin loss from inflamed intestine causes oedema and pleural or abdominal effusion. Chronic small intestinal disease welfare assessment includes body condition, appetite, energy levels, and frequency of vomiting—welfare impact extends well beyond gastrointestinal signs alone.
Chronic large bowel disease (colitis) causes frequent defecation, mucus in faeces, haematochezia, and urgency. While less likely to cause nutritional compromise than small bowel disease, the urgency and frequency of defecation causes significant welfare impact through apparent distress and housetraining accidents. Dietary management (highly digestible diets, high-fibre diets, novel protein elimination diets) addresses many cases. Metronidazole reduces luminal inflammation and Clostridioides overgrowth. Prednisolone is reserved for confirmed inflammatory disease.
Toxocara canis (roundworm), Trichuris vulpis (whipworm), Giardia, Cryptosporidium, and Tritrichomonas foetus cause varying degrees of intestinal welfare compromise. Regular faecal examinations enable targeted antiparasitic treatment rather than empirical broad-spectrum deworming. Giardia causes chronic intermittent diarrhoea that profoundly affects quality of life; fenbendazole treatment over 5 days achieves clearance in most cases. Tritrichomonas in young cats causes refractory large bowel diarrhoea requiring ronidazole treatment.
Systematic diagnosis through faecal examination (culture, parasitology, ELISA for Giardia), serum B12/folate (indicating proximal vs. distal small bowel disease), trypsin-like immunoreactivity (TLI for exocrine pancreatic insufficiency), and intestinal biopsy where indicated reduces empirical treatment cycles and provides faster welfare improvement. Cobalamin (B12) supplementation improves welfare outcomes in intestinal disease—deficiency impairs mucosal healing and immune function.